

Bronchiectasis Clinical Trial:

What is the study about?

This study is testing whether a new medication (the Investigational drug) can help reduce flare-ups (exacerbations) in people with bronchiectasis.

Who can take part?

- Adults 18 years and older
- Must have bronchiectasis confirmed on a CT scan
- Must regularly produce sputum
- Must have had flare-ups/exacerbations in the past

Not eligible if:

- Main diagnosis is asthma or COPD
- Bronchiectasis caused by cystic fibrosis or certain immune disorders

What's involved?

- Will be assigned randomly into one of two groups (Investigational drug or placebo).
- The entire study participation lasts around 1 year and 8 months.
- Will complete symptom diaries on a smartphone.
- Velocity Research Physicians monitor patient health closely throughout.

What is being measured?

The main aim is to see whether the Investigational drug helps reduce the number of bronchiectasis flare-ups compared to placebo. Doctors will also monitor and check:

- Overall health changes, any unwanted effects, how symptoms change over time

Why take part?

- Access a new possible treatment for bronchiectasis and receive regular monitoring
- Contribute to improving bronchiectasis care for future patients

What should patients know?

- It's a well-structured scientific study, authorised by the Medicine and Healthcare Products Regulatory Agency (MHRA)
- All participants will get regular follow-ups and medical assessments for the trial duration.
- There's no guarantee of benefit, but they will be helping to advance research for future patients